, Jan. 15, 2013
/PRNewswire/ -- Dune Medical Devices, Inc. announced today the Company has opened a new headquarters office at 25 Thomson Place, which is part of the growing Innovation District on the South Boston Waterfront. The relocation follows the recent Federal Drug Administration (FDA) approval of its flagship product, the MarginProbe® System, a breakthrough intra-operative tissue assessment device for early-stage breast cancer surgery.
"The FDA approval of MarginProbe in the U.S. is a major milestone for Dune, and an opportune time to upgrade our facilities in anticipation of robust growth in 2013. The Innovation District was an attractive location due to its reputation as a mecca for emerging medical technology in the Boston area," said Dan Levangie, chief executive officer of Dune Medical Devices.
The new headquarters will accommodate the expansion of several departments throughout 2013, including operations, sales & marketing and clinical & regulatory, to support the commercialization of MarginProbe in the U.S. and ongoing exploration of the technology's potential applications.
MarginProbe has been available in Europe since 2008 and is now available in select locations throughout the U.S., with national availability expected in early 2013. For more information, please visit www.dunemedical.com.
About Dune Medical Devices
Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications.
Dune Medical Devices is a privately held company financed by Apax Partners since 2004. It has offices in the U.S., Israel, Germany and Switzerland.
Dune Medical Devices
The Ruth Group
SOURCE Dune Medical Devices, Inc.